Quest Diagnostics Incorporated (NYSE:DGX) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Quest Diagnostics Incorporated (NYSE:DGXGet Free Report) have received an average rating of “Hold” from the ten ratings firms that are presently covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $146.91.

A number of brokerages have recently issued reports on DGX. Bank of America raised Quest Diagnostics from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $140.00 to $160.00 in a research note on Tuesday, December 12th. Jefferies Financial Group raised Quest Diagnostics from a “hold” rating to a “buy” rating and boosted their target price for the company from $140.00 to $155.00 in a research report on Wednesday, February 7th. StockNews.com lowered Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Thursday, February 1st. TheStreet lowered Quest Diagnostics from a “b-” rating to a “c” rating in a research report on Monday, February 5th. Finally, JPMorgan Chase & Co. boosted their target price on Quest Diagnostics from $148.00 to $149.00 and gave the company a “neutral” rating in a research report on Friday, November 17th.

Read Our Latest Research Report on Quest Diagnostics

Quest Diagnostics Trading Up 2.6 %

Shares of DGX opened at $130.01 on Thursday. The firm has a market cap of $14.62 billion, a price-to-earnings ratio of 17.36, a PEG ratio of 2.73 and a beta of 0.92. Quest Diagnostics has a 52-week low of $119.59 and a 52-week high of $148.91. The business’s fifty day moving average is $134.16 and its 200-day moving average is $131.42. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.20 and a current ratio of 1.31.

Quest Diagnostics (NYSE:DGXGet Free Report) last announced its earnings results on Thursday, February 1st. The medical research company reported $2.15 EPS for the quarter, topping the consensus estimate of $2.11 by $0.04. The firm had revenue of $2.29 billion for the quarter, compared to the consensus estimate of $2.25 billion. Quest Diagnostics had a return on equity of 15.79% and a net margin of 9.23%. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.98 EPS. Equities analysts anticipate that Quest Diagnostics will post 8.78 EPS for the current fiscal year.

Quest Diagnostics Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 22nd. Shareholders of record on Monday, April 8th will be issued a dividend of $0.75 per share. This is a positive change from Quest Diagnostics’s previous quarterly dividend of $0.71. This represents a $3.00 dividend on an annualized basis and a yield of 2.31%. The ex-dividend date is Friday, April 5th. Quest Diagnostics’s payout ratio is currently 37.92%.

Institutional Trading of Quest Diagnostics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DGX. Park Place Capital Corp grew its holdings in shares of Quest Diagnostics by 73.4% in the second quarter. Park Place Capital Corp now owns 189 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 80 shares in the last quarter. Altshuler Shaham Ltd bought a new position in shares of Quest Diagnostics in the fourth quarter valued at approximately $26,000. Pacifica Partners Inc. bought a new position in shares of Quest Diagnostics in the third quarter valued at approximately $25,000. Chilton Capital Management LLC bought a new position in shares of Quest Diagnostics in the first quarter valued at approximately $28,000. Finally, NBC Securities Inc. bought a new position in shares of Quest Diagnostics in the third quarter valued at approximately $25,000. 87.76% of the stock is owned by institutional investors.

Quest Diagnostics Company Profile

(Get Free Report

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Featured Stories

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.